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Several chronic studies in rats indicating that cadmium exposure can induce tumors of the ventral prostate have recently been completed in our lab-
oratory. In one such study, a single dose of cadmium, s.c., increased prostatic tumor incidence only at doses below 5.0 pmol/kg, the approximate
threshold for cadmium-induced testicular damage. In a further study, prostatic tumors were elevated with higher doses of cadmium (30 pmol/kg,
s.c.) if testicular damage was prevented by zinc pretreatment. Most recently, we found that dietary cadmium (25 to 200 pg/g) also can increase pro-
static neoplastic lesions, but these were reduced by zinc-deficient diets. Thus it appears that cadmium produces prostatic tumors only if testicular
function is maintained. Furthermore, we find that metallothionein (MT), a protein associated with cadmium tolerance, may be deficient in the rat
prostate, and the prostatic MT gene, at least in the ventral lobe, is unresponsive to metal stimuli. In liver, MT gene expression, as assessed by MT-I
mRNA, was quite apparent in control tissue and was induced in a dose-dependent manner 24 hr following cadmium exposure (1 to 10 pmol/kg,
s.c.). However, in the ventral prostate very low constitutive levels of MT-I mRNA were detected and increases did not occur with cadmium expo-
sure. Cadmium concentrations in the ventral prostate were in excess of those that cause significant induction in the liver. In sharp contrast to the
gene in the ventral prostate, in the dorsal prostate the MT gene was quite active. The dorsal prostate is not susceptible to cadmium carcinogenesis.
The association between tissue-specific quiescence of the MT gene and susceptibility to cadmium carcinogenesis deserves further study.
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Introduction
Cadmium is a highly toxic metal that is
cause for elevated environmental and occu-
pational concern due to increasing expo-
sure of humans. In animal models,
cadmium is a potent carcinogen that is
capable ofinducing a variety of tumors (for
review see 1); both the lung (2) and more
recently the prostate (3-5) have been iden-
tified as target sites for cadmium-induced
tumors. In humans, cadmium is classified
by the IARC as a suspected human car-
cinogen (Group 2A) with the lung and
possibly the prostate as target organs (6,7).
The exact mechanism ofcadmium car-
cinogenesis is unknown. However, the level
of metallothionein (MT) gene expression
may play a role in determining a tissues's
susceptibility to cadmium-induced tumors.
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MT is a low molecular weight (6000 to
7000 daltons) metal binding protein, the
amino acid content of which is approxi-
mately 30% cysteine residues (8). This
high content of cysteinyl thiol groups
accounts for the high metal affinity ofMT
(8). Although MT is found in a variety of
eukaryotic cells, its physiologic functions
are still unknown. However, MT appears
to function, in part, in cellular defenses
against metal toxicity (9). In particular,
MT appears to play an important role in
providing protection from cadmium toxic-
ity. It is possible that reduced levels ofMT
gene expression may lead to an increase in
a tissue's susceptibility to cadmium car-
cinogenesis.
A number of studies from our labora-
tory have demonstrated that the rat ventral
prostate is a target site for cadmium-
induced tumors. (3-5). The following will
summarize these studies, as well as provide
new data with regard to MT gene expres-
sion in this target for cadmium carcino-
genicity.
In the first study, male Wistar
[Crl:(WI)BR) rats were given a single s.c.
dose of cadmium (0, 1, 2.5, 5, 10, 20, or
40 pmole/kg) and studied over a 2 year
period (3). A strong positive correlation
was established between the dose of cad-
mium and the incidence and multiplicity
of prostatic tumors for doses up to 2.5
pimole/kg. A significant increase in prosta-
tic tumor incidence was demonstrated at
the 2.5 pmole/kg dose ofcadmium with 8
adenomas/26 rats at risk (31%). Prostatic
tumors occurred exclusively in the ventral
lobe. At higher doses of cadmium (>2.5
pmole/kg), an increased incidence in pro-
static tumors did not occur. However,
these doses were associated with testicular
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Figure 1. Basal metallothionein gene expression in vari-
ous tissues of the Wistar rat. RNA was isolated, dena-
tured, and slot-blotted onto Nytran. Blots were probed
with a 32p labeled p2A10 plasmid specific for the MT-I
gene. Equal loading of RNA was confirmed by 3-actin
geneexpression.
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Figure 2 Effectofcadmium on metallothionein gene expression in liverand ventral prostate oftheWistar rat. Animals
weretreatedwithcadmium, sc, and metallothionein gene expression determinedat24hr. RNAwas isolated,denatured,
and slot-blotted onto Nytran. Blotswere probedwith a32p labeled p2A10 plasmid specificforthe MT-I gene. Equal load-
ing ofRNAwasconfirmed by 3-actin gene expression.
degeneration and atrophy. A strong posi-
tive correlation between cadmium and
multiplicity of hyperplastic foci was
demonstrated at doses up to and including
20 jimole/kg. These data indicate that cad-
mium will induce preneoplastic lesions that
develop into tumors only when doses of
cadmium that are given are well below
those which induce testicular degeneration
and loss offunction.
In a second study, the ability ofzinc to
modify the carcinogenic effect ofcadmium
was investigated in male Wistar rats (4).
Groups ofrats received a single s.c. or i.m.
injection of cadmium (30 limole/kg) and
zinc was given in three separate s.c. doses of
100, 300, or 1000 pmole/kg. In groups in
which cadmium-induced testicular tumors
and chronic testicular degeneration were
prevented by zinc (1000 pmole/kg), a
marked elevation in prostatic tumors
occurred (control, 9.6%; cadmium + high
zinc, 29.6%). In addition, cadmium when
administered i.m. did not result in testicu-
lar degeneration but induced an elevated
incidence of prostatic tumors (42.3%).
Prostatic tumors were exclusively adenomas
and occurred only in the ventral prostate.
When all cadmium treated groups were
combined, regardless of other treatments,
there was a significant increase in prostatic
tumor incidence (51 tumor bearing
rats/199 rats; 26%) as compared with con-
trols (8/83; 10%).
In a third study, male Wistar
(WF/NCr) rats received dietary cadmium
(25 to 200 pg/g) mixed in diets either ade-
quate (60 pg/g) or deficient (7pig/g) in zinc
(5). A significant elevation in the overall
incidence of prostatic proliferative lesions
(focal atypical hyperplasia and adenomas)
occurred in animals given cadmium and
zinc-adequate diets (12 rats with lesions/97
rats at risk; 12%) as compared to animals
given cadmium and zinc-deficient diets
(5/103; 5%) or controls (1/54; 2%).
Lesions occurred exclusively in the ventral
prostate. The lower incidence of prostatic
proliferative lesions in the zinc-deficient
rats was associated with an increase in pro-
static atrophy, with adequate and deficient
animals exposed to cadmium resulting in
24% and 39% atrophy, respectively.
Table 1. Basal zincand metallothionein levels in various tissues ofthe maleWistar rat.
Metallothionein1,2 Zinc1,2
(pg/g wetweight) (pg/g wetweight)
Ventral Prostate 1.21 ±0.35(4)4 13.67±7.3(11)B
DorsolateralProstate 28.46 ± 8.63(4)8 139.3 ± 32.1 (11)b
Liver 3.96 ± 1.03(4)C 21.3 ± 2.8(1 )a
'Values represent the mean + S.D. (n). 2Values not sharing a common letter are significantly different. p < 0.05.
Metallothionein, capital letters. Zinc, lower case.
These chronic studies in rats establish
that the rat ventral prostate is a target for
cadmium-induced tumors. Hyperplastic
lesions were evident at high doses of cad-
mium in the absence ofan increase in pro-
static tumors (3), and the lack ofincreased
prostatic tumor formation at higher doses
parallels a loss oftesticular function. These
studies demonstrate the importance of tes-
ticular function in the development, but
not initiation, ofprostatic tumors.
Since MT is thought to provide protec-
tion against the toxic effects of cadmium,
we hypothesized that the increased suscep-
tibility to cadmium carcinogenicity
demonstrated for the ventral prostate may
be due to alterations in MT gene expres-
sion. One possible pathway for cadmium
carcinogenicity may involve the interaction
of cadmium with DNA, either directly or
indirectly. Previous studies in our labora-
tory have shown that an increase in MT
gene expression can reduce the level of
DNA damage associated with cadmium
exposure (10). Hence, a deficiency of MT
may contribute to a tissue's susceptiblity to
cadmium carcinogenicity. Therefore, we
investigated MT production and gene
expression in the ventral prostate as well as
in the dorsolateral prostate and liver, two
tissues that are not targets for cadmium
carcinogenicity in the rat.
Metallothionein levels were determined
using the Onosaka assay (11) as modified
by Eaton and Toal (12). Basal MT levels
were determined in liver, ventral prostate
and dorsolateral prostate and are presented
in Table 1. Zinc levels were determined by
atomic absorption and basal tissue levels
are presented also in Table 1. MT levels in
10
i 1.0
0
E 0.1
a
E
01
0.0
0 12 24 36 48
Time (hrs)
Figure3. Cadmium accumulation invarioustissuefollow-
ing administration of a dose of cadmium carcinogenic to
the prostate. Animals were administered cadmium (2.5
pmole/kg, s.c.) using a dose known to induce prostatic
tumors. Tissue cadmium content was determined as a
function of time by atomic absorption spectrometry. Data
representthe mean ± S.D.(n=4)
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Table2. Effect of increasing doses ofcadmium on metallothionein levels in varioustissues ofthe rat.
Cadmium
(pmole/kg) Liver1'2 Ventral prostate1'2
0 3.96 ± 1.03A 1.21 ± 0.35a
0.5 24.20 ± 10.68 0.95 ± 0.09a
1.0 33.48 ±6.99C 0.85 ± 0.48a
2.5 79.07 ±5.45D 0.99 ± 0.27a
5.0 127.35 ± 5.06E 1.74 ±0.198
10.0 170.75 ±41.2F 1.22±0.31a
'Values represent the mean ± S.D. (n =4to 8). A/alues not sharing a common letter are significantly different. p < 0.05.
Liver, capital letters. Ventral prostate, lowercase.
the dorsolateral prostate were significantly
higher than those ofeither the liver or ven-
tral prostate. In addition, liver MT levels
were greater than that of the ventral
prostate. In general, MT levels correlated
with zinc tissue levels for the tissues exam-
ined. The dorsolateral prostate had the
greatest zinc content and in turn, the high-
est MT levels. Although the liver and ven-
tral prostate were not significantly different
in zinc content, the liver did contain signif-
icantly greater basal MT levels. Ventral
prostate contained very low basal levels of
MT, almost at the limit of detection with
this assay (12).
Analysis of MT mRNA from each tis-
sue correlated with the data obtained from
the MT protein assay (Figure 1). Total
RNA was isolated using RNAzol, dena-
tured with glyoxal and slot-blotted onto
Nytran, as previously described (10). RNA
integrity was determined by electrophoresis
and message size confirmed by northern
analysis. Northern transfers and slot-blots
were probed for MT-I gene expression
using a 32P-labeled p2A10 plasmid for the
MT-I gene generously supplied by Dr. H.
Herschman (13). RNA loading was stan-
dardized to 3-actin gene expression. MT-I
gene expression was greatest in the dorso-
lateral prostate and was very low in the
ventral prostate. Similar data were obtained
with probes specific for MT-II RNA.
The ability ofcadmium to induce MT
was investigated in the liver and ventral
prostate. MT levels are presented in Table
2. Animals were exposed to cadmium s.c.
and MT levels were assessed at 24 hr.
Increasing doses of cadmium resulted in
increased MT and this induction was linear
throughout the dose range examined. In
contrast, MT was not induced in the ven-
tral prostate following doses up to and
including 10 pmole/kg. Analysis of MT-I
gene expression resulted in findings similar
to that for MT protein levels (Figure 2).
Increased amounts of MT-I mRNA were
detected in samples obtained from the liv-
ers ofrats treated with various doses ofcad-
mium. Increased levels ofMT gene expres-
sion were not demonstrated in the ventral
prostate 24 hr following administration of
cadmium.
Since a dose of2.5 jimole/kg cadmium
resulted in an increased incidence of
tumors in the ventral prostate but not the
dorsolateral prostate or liver, the tissue dis-
tribution of cadmium following this dose
was examined. These data are presented in
Figure 3. Cadmium levels were maximal at
the first time point examined, 6 hr, and
were persistent through 48 hr. Liver cad-
mium levels were the highest ofthe tissues
examined with values approximately 10-
fold higher than that of the dorsolateral
prostate and approximately 60-fold higher
than that of the ventral prostate. Similar
levels of cadmium as obtained in the ven-
tral prostate were sufficient to stimulate the
MT gene in the liver (not shown).
Interestingly, accumulation of cadmium
within the ventral prostate is the lowest of
the three tissues examined although the
ventral prostate is a target for cadmium
carcinogenesis. Clearly, factors other than
distribution ofcadmium play an important
role in the development ofventral prostatic
tumors.
In summary, we have found that the rat
ventral prostate is a target for cadmium
carcinogenesis. Metallothionein gene activ-
ity is quiescent in the ventral prostate. This
tissue-specific quiescence of the metalloth-
ionein gene may determine a tissue's sus-
ceptibility to cadmium carcinogenesis.
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